News und Analysen
![Premier Inc. Analysis: Complications & Common Chronic Conditions Increase Hospitals’ Childbirth Costs by 20 Percent or More](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Premier Inc. Analysis: Complications & Common Chronic Conditions Increase Hospitals’ Childbirth Costs by 20 Percent or More
U.S. hospitals could save upwards of 20 percent in costs for complicated childbirths, according to a nationally representative analysis by Premier Inc. (NASDAQ: PINC). The increased costs
![Dexcom to Present at 38th Annual J.P. Morgan Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Dexcom to Present at 38th Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 38th annual J.P. Morgan Healthcare
![Dexcom to Present at 38th Annual J.P. Morgan Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Dexcom to Present at 38th Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 38th annual J.P. Morgan Healthcare
![Illumina and Pacific Biosciences Announce Termination of Merger Agreement](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Illumina and Pacific Biosciences Announce Termination of Merger Agreement
Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on
![Illumina and Pacific Biosciences Announce Termination of Merger Agreement](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Illumina and Pacific Biosciences Announce Termination of Merger Agreement
Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on
![Illumina and Pacific Biosciences Announce Termination of Merger Agreement](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Illumina and Pacific Biosciences Announce Termination of Merger Agreement
Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on
![NanoString to Present at the 38th Annual JP Morgan Healthcare Conference](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
NanoString to Present at the 38th Annual JP Morgan Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that the company’s management is scheduled to present at the 38th
![Pulmatrix: NBC-Empfehlung explodiert nach Big-Pharma-Deal](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Pulmatrix: NBC-Empfehlung explodiert nach Big-Pharma-Deal
Für den No Brainer Club überträgt sich das gigantische Momentum von Ende 2019 ohne Unterbrechung ins neue Jahr: Mit Pulmatrix (WKN: A2PD3T) explodiert heute einer der letzten unten gebliebenen No
![Agilent Expands Cross-Vendor CDS Instrument Control](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Agilent Expands Cross-Vendor CDS Instrument Control
Agilent Technologies Inc. (NYSE: A) today announced the latest implementation of its mutual compatibility philosophy. Now, joint customers of Agilent Technologies and Thermo Fisher Scientific can
![LION E-Mobility: Nach dem Deal ist vor der Rallye?](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
LION E-Mobility: Nach dem Deal ist vor der Rallye?
LION E-Mobility (WKN: A140QA) hatte mit der kanadischen Firma "The Lion Electric Co." vor Weihnachten einen „Multimillionen-Serienliefervertrag über BMW-Batterien“ geschlossen. Nun gibt das
![Agilent Compliance Services Voted No. 1 in Global Survey](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Agilent Compliance Services Voted No. 1 in Global Survey
Agilent Technologies Inc. (NYSE: A) today announced that the company’s ability to help laboratories comply with government regulations has been ranked second to none in a global survey.
Cell
![Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled
![Cidara und Otonomy: Weitere NBC-Favoriten knallen durch die Decke](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Cidara und Otonomy: Weitere NBC-Favoriten knallen durch die Decke
Aktien von Cidara Therapeutics (WKN: A14R2R) und Otonomy (WKN: A119VZ) gehörten vergangene Woche mal wieder zu den Gewinnern im Biotech-Sektor. Stehen hier ähnliche Entwicklungen an wie jüngst bei
![LION E-Mobility: Serienliefervertrag für E-Schulbusse fix](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
LION E-Mobility: Serienliefervertrag für E-Schulbusse fix
LION E-Mobility (WKN: A140QA) wird Serienlieferant von Batterien für E-Schulbusse und E-LKWs. Dazu schloss das Unternehmen einen „potentiellen Multimillionen-Serienliefervertrag über BMW-Batterien“.
![Qiagen: Übernahme geplatzt – so kann es jetzt weitergehen](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Qiagen: Übernahme geplatzt – so kann es jetzt weitergehen
Qiagen-Aktien (WKN: A2DKCH) verbilligen sich heute um -18,93% auf 30,02 Euro. Der Grund sind gescheiterte Übernahmegespräche.
Die Gespräche mit möglichen Übernahme-Interessenten würden nun beendet
![Qiagen: Übernahme geplatzt – so kann es jetzt weitergehen](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Qiagen: Übernahme geplatzt – so kann es jetzt weitergehen
Qiagen-Aktien (WKN: A2DKCH) verbilligen sich heute um -18,93% auf 30,02 Euro. Der Grund sind gescheiterte Übernahmegespräche.
Die Gespräche mit möglichen Übernahme-Interessenten würden nun beendet
![Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak
![Illumina to Webcast Upcoming Investor Conference Presentation](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina to Webcast Upcoming Investor Conference Presentation
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invite investors to participate via webcast.
J.P. Morgan Healthcare
![Illumina to Webcast Upcoming Investor Conference Presentation](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina to Webcast Upcoming Investor Conference Presentation
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invite investors to participate via webcast.
J.P. Morgan Healthcare
![Illumina to Webcast Upcoming Investor Conference Presentation](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina to Webcast Upcoming Investor Conference Presentation
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invite investors to participate via webcast.
J.P. Morgan Healthcare
![Intra-Cellular Therapies: Nächster Volltreffer von BB Biotech!](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Intra-Cellular Therapies: Nächster Volltreffer von BB Biotech!
Bereits vor wenigen Tagen hatte ich hier bei sharedeals.de über die Forschungserfolge sowie dem damit verbundenen Kurssprung in der Aktie von Myovant Sciences berichtet. Heute nun hat die Schweizer
![Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND). Pfizer is
![Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it has entered into a definitive agreement for a private placement with institutional investors to purchase an
![Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases
![Agilent Technologies to Present at J.P. Morgan Healthcare Conference](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Agilent Technologies to Present at J.P. Morgan Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced the following presentation will be webcast for the investor community:
What: 38th Annual J.P. Morgan Healthcare Conference
Where: The Westin